Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Patrick S. Chaftari Image

      Patrick S. Chaftari, MD, MBA, MS, FACP

      Department of Emergency Medicine, Division of Internal Medicine

      About Dr. Patrick S. Chaftari

      Dr. Patrick Chaftari is a Professor in the Department of Emergency Medicine at the University of Texas MD Anderson Cancer Center, he is also the Clinical Medical Director of the Clinical Decision Unit (CDU), Chair of the institution Unitization Review and is a staff physician in the Emergency Center. He is board-certified in Internal Medicine and joined MD Anderson in 2009. Additionally, Dr. Chaftari obtained a strategic MBA from the University of Houston and is a Diplomate of the American Board of Quality Assurance and Utilization Review Physician (ABQAURP) with a Physician Advisor certification (CHCQM-PHYADV). HCQM certification demonstrates that Diplomates have the practical knowledge and the tools that can reduce medical errors, ensure patient safety, eliminate waste and unnecessary services, while avoiding potentially harmful delays in care.

      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Lead Physician Advisor, The University of Texas MD Anderson Cancer Center, Houtson, TX

      Medical Director, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Professor, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2024University of Texas Health, US, Data Science, MS in Biomedical Informatics
      2019University of Houston Victoria, Houston, Texas, US, Strategic MBA, MBA
      1992Saint Joseph University, Beirut, LB, MD

      Postgraduate Training

      1997-2000Clinical Residency, Internal Medicine, Staten Island University Hospital, Staten Island, New York
      1996-1997Clinical Internship, Internal Medicine, Staten Island University Hospital, Staten Island, New York
      1995-1996Clinical Internship, Surgery, Staten Island University Hospital, Staten Island, New York
      1993-1995Clinical Residency, Orthopedic Surgery, Lebanese University, Beirut

      Licenses & Certifications

      2020American Board of Quality Assurance & Utilization Review Physicians
      2006Medical License
      1999American Board of Internal Medicine

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

      Assistant Professor, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2018

      Assistant Professor, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2010

      Administrative Appointments/Responsibilities

      Lead Physician Advisor, VP Inpatient Medical operations and ECMS, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

      Medical Director, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

      Schedule Administrator, Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2019

      Medical Director, Home Health, Oakdale, LA, 2005 - 2006

      ER Medical Director, Oakdale Community Hospital, Oakdale, LA, 2004 - 2008

      Associate Chief of Staff, Oakdale Community Hospital, Oakdale, LA, 2004 - 2004

      Chief Medical Resident, Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, 1999 - 2000

      Other Professional Positions

      Project Team Leader, Observation Project /Self Denial Short Stays reviews, UT MD Anderson Cancer Center, Houston, TX, 2019 - 2022

      Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2009

      Internist, Chaftari Medical Inc, Kinder, LA, 2003 - 2006

      ER Physician, Oakdale Community Hospital, Oakdale, LA, 2002 - 2004

      Internist, SAHA Medical, Kinder, LA, 2002 - 2003

      Internist, Total Care Medical Center, Plaquemine, LA, 2000 - 2002

      Extramural Institutional Committee Activities

      Member, Transfusion & Blood Management Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Chair, Utilization Review, The University of Texas MD Anderson Cancer Center, 2022 - 2025

      Co-Chair, Utilization Review, The University of Texas MD Anderson Cancer Center, 2021 - 2022

      Member, Utilization Review, The University of Texas MD Anderson Cancer Center, 2019 - 2020

      Officer, EHR, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2012 - 2018

      Member, CPR Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016

      Honors & Awards

      2022 - 2023Research Division of Internal Medicine Research & Quality Improvement Award winner, MDACC
      2012 - 2023Fellow, American College of Physician
      2001Richmond County Society Research Competition Award, Richmond County Society Research

      Professional Memberships

      American Medical Informatics Association

      2024 - Present

      American Board of Quality Assurance ad Utilization Physicians

      2020 - Present

      American College of Physician Advisors

      2019 - Present

      Association of Physician Leadership in Care Management (APLCM)

      2019 - Present

      American Pain Society (APS)

      2011 - 2013

      Multinational Association of Supportive Care in Cancer (MASCC)

      2011 - 2013

      Harris County Medical Society

      2006 - Present

      American College of Physicians (ACP)

      1998 - Present

      Lebanese Order of Physicians

      1992 - Present

      Selected Presentations & Talks

      Regional Presentations

      1. 2009. Emergency Center Observation Unit. Conference. University of Texas. Austin, TX, US.

      National Presentations

      1. 2023. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) inthe Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients. Conference. IDWeek 2023. Boston, MA, US.
      2. 2020. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies. Conference. ID Week 2020. Virtual Conference,, US.
      3. 2020. The Role of Procalcitonin (PCT) and Lactic Acid in Febrile Neutropenic Cancer Patients in an Oncological Emergency Center. Conference. ID Week 2020. Virtual Conference,, US.
      4. 2020. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation,. Conference. ID Week 2020. Virtual Conference,, Online, US.
      5. 2019. The Impact of Checkpoint Inhibitor Immunotherapy on Infections in Lung Cancer Patients. Conference. ID Week. Washington, DC, US.
      6. 2019. Immune Checkpoint Therapy, MDAnderson Experience. Invited. N/A. Houston, TX, US.
      7. 2018. Management of Hemoptysis in the EC. Invited. N/A. Houston, TX, US.
      8. 2017. Improvement of Smoking Abstinence Rates with increased Varenicline Dosage:. Conference. the Society of Research on Nicotine and Tobacco, US.
      9. 2013. Utilization of Oncologic Emergency Department Observation Units by Cancer Patients Presenting with Pain. Conference. UT MDACC. Houston, TX, US.
      10. 2000. The outcome of patients with obstructive sleep apnea after gastric bypass surgery. Conference. ACCP. Las Vegas, NV, US.
      11. 1999. Characteristics of patients with negative sleep studies. Conference. ACCP. Chicago, IL, US.
      12. 1999. The usefulness of the Epworth Sleepiness Scores alone as a predictor of sleep study outcomes. Conference. ACCP. Chicago, IL, US.

      International Presentations

      1. 2017. Emergency Department Intervention Program for Enhancing Choice at the End of Life. Conference. MEMC-Great 2017. Lisbon, PT.
      Read More
      Less

      Selected Publications

      Peer-Reviewed Articles

      1. Nath, S, Qdaisat, AZ, Derkach, A, Babar, A, Zalavadia, D, Chaftari, P, Li, Z, Wattana, M, Schmeltz, J, Johnston, RP, Ortiz, EJ, Alagappan, K, Klotz, A, Yeung, SJ. Development and Validation of a Prognostic Risk Score for Patients With Cancer and Neutropenic Fever Presenting to the Emergency Department. JACEP Open 7(2), 2026. e-Pub 2026. PMID: 41783382.
      2. Singer E, Elsayem A, Rodriguez C, Zoghbi M, Dagher J, Yammine N, Kamal M, Cruz Carreras MT, Vu T, Qdaisat A, Yeung SJ, Chaftari P. Management and disposition of metastatic spinal cord compression in the emergency department: A review of the literature. Annals of Medicine 57, 2025. e-Pub 2025. PMID: 41033840.
      3. Wehbe, S, Chaftari, AP, Hachem, RY, Dagher, H, Haddad, AJ, Philip, A, Jiang, Y, Zakhour, R, Bakht, P, Shrestha, J, Lamie, PM, Sherchan, R, Makhoul, J, Chaftari, P, Raad, II. Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis. Journal of Fungi 11(5), 2025. e-Pub 2025. PMID: 40422689.
      4. Dagher, H, Chaftari, AP, Haddad, AJ, Jiang, Y, Shrestha, J, Sherchan, R, Lamie, PM, Makhoul, J, Chaftari, P, Hachem, RY, Raad, II. Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment. Journal of Fungi 11(2), 2025. e-Pub 2025. PMID: 39997454.
      5. Hachem, RY, Dagher, H, Chaftari, AP, Jiang, Y, Haddad, AJ, Wehbe, S, Shrestha, J, Sherchan, R, Lamie, PM, Makhoul, J, Chaftari, P, Raad, II. Decreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents. Journal of Fungi 11(2), 2025. e-Pub 2025. PMID: 39997413.
      6. Burk, KJ, Stroh, JJ, Larkin, K, Chaftari, P, Langabeer, DM, Menendez, JR, Woodruff, JF, Hargrave, J, Zhu, H, Long, JP, Yeung, SJ, Alagappan, K, Qdaisat, AZ. Empathy Unmasked: A Randomized Controlled Trial Evaluating Patient Perception of Physician Empathy in Oncologic Emergency Setting Wearing Personal Protective Equipment versus Unmasked Video Communication. Journal of Emergency Medicine 68:43-53, 2025. e-Pub 2025. PMID: 39800593.
      7. Qdaisat, AZ, Stroh, E, Reyes-Gibby, CC, Wattana, M, Viets-Upchurch, J, Li, Z, Page, VD, Fatima, H, Chaftari, P, Elsayem, A. Severity of Symptoms as an Independent Predictor of Poor Outcomes in Patients with Advanced Cancer Presenting to the Emergency Department. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682175.
      8. Dagher, H, Chaftari, AP, Hachem, RY, Jiang, Y, Philip, A, Mulanovich, P, Haddad, AJ, Lamie, PM, Dib, RW, John, TM, Dailey Garnes, NM, Ali, S, Chaftari, P, Raad, II. Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia. Cancers 16(20), 2024. e-Pub 2024. PMID: 39456544.
      9. Chaftari AM, Dagher H, Hachem R, Jiang Y, Lamie P, Wilson Dib R, John T, Haddad A, Philip A, Alii S, Mulanovich P, Yuan Y, Chaftari P, Raad I. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. J Antimicrob Chemother 79(10):2543-2553, 2024. e-Pub 2024. PMID: 39092963.
      10. Aiham Qdaisat MD, Demis Lipe MD, Pavitra Krishnamani MD, Trung D Nguyen MS, Patrick Chaftari MD, Aswin Srinivasan DO, Elkin Galvis-Carvajal MD, Reyes-Gibby DrPH CC, Monica K Wattana MD. The lethal M triad of myocarditis, myositis, and myasthenia gravis post immune checkpoint inhibitors therapy: A systematic review. The Journal of Emergency Medicine 66(6), 2024. e-Pub 2024.
      11. Haddad AJ, Hachem RY, Moussa M, Jiang Y, Dagher HR, Chaftari P, Chaftari AM, Raad II. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473412.
      12. Chaftari A, MD, Dagher H, MD, Hachem RY, MD, PhD, Jiang Y, MS, Lamie P, DO, Dib RW, MD, John T, MD, Haddad A, MD, Philip A, RN, Ali S, RN, Mulanovich P, Juan Y, MD, Chaftari P, MD, Raad II, Professor D. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia. Open Forum Infectious Diseases 10(2), 2023. e-Pub 2023.
      13. Dagher H, Chaftari AM, Hachem RY, Jiang Y, Philip A, Mulanovich P, Haddad A, Lamie P, Dib RW, John T, Garnes NJD, Chaftari P, Raad II. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients. Open Forum Infect Diseases 10(2), 2023. e-Pub 2023.
      14. Singer ED, Faiz SA, Qdaisat A, Abdeldaem K, Dagher J, Chaftari P, Yeung SJ. Hemoptysis in Cancer Patients. Cancers (Basel) 15(19):4765, 2023. e-Pub 2023. PMID: 37835458.
      15. Lipe DN, Qdaisat A, Chaftari P, Wattana MK, Krishnamani PP, Reyes-Gibby C, Yeung SJ. Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy. Front Oncol 13:1122329, 2023. e-Pub 2023. PMID: 37007139.
      16. Dagher H, Chaftari AM, Subbiah IM, Malek AE, Jiang Y, Lamie P, Granwehr B, John T, Yepez E, Borjan J, Reyes-Gibby C, Flores M, Khawaja F, Pande M, Ali N, Rojo R, Karp DD, Chaftari P, Hachem R, Raad II. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife 12:e81182, 2023. e-Pub 2023. PMID: 36748905.
      17. Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Effort Team DDFCOD, Kontoyiannis DP, Malek AE, Chaftari AM. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. Elife 12, 2023. e-Pub 2023. PMID: 36715684.
      18. Krishnamani PP, Qdaisat A, Wattana MK, Lipe DN, Sandoval M, Elsayem A, Cruz Carreras MT, Yeung SJ, Chaftari PS. Characteristics and Outcomes of Patients with Cancer Pain Placed in an Emergency Department Observation Unit. Cancers (Basel) 14(23), 2022. e-Pub 2022. PMID: 36497353.
      19. Elsayem AF, Warneke CL, Reyes-Gibby CC, Buffardi LJ, Sadaf H, Chaftari PS, Brock PA, Page VD, Viets-Upchurch J, Lipe D, Alagappan K. "Triple Threat" Conditions Predict Mortality Among Patients With Advanced Cancer Who Present to the Emergency Department. J Emerg Med 63(3):355-362, 2022. e-Pub 2022. PMID: 36220672.
      20. Raad I, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Cruz AF, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragivich T, Kiat YEV, Fakhreddine S, Hanna PA, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Guevara EY, Torres H, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, Á G, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Effort Team DDFCOD, Kontoyiannis DP, Malek AE, Chaftari AM. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship. medRxiv, 2022. e-Pub 2022. PMID: 36097568.
      21. Lipe DN, Qdaisat A, Rajha E, Al-Breiki A, Cruz Carreras MT, Chaftari P, Yeung SJ, Rice TW. Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis. Res Pract Thromb Haemost 6(6):e12761, 2022. e-Pub 2022. PMID: 36000091.
      22. Lipe DN, Chaftari P, Reyes-Gibby C, Palaskas NL. The evolving landscape of chimeric antigen receptor T-cell therapy associated cardiotoxicity. Am J Emerg Med 10(1016):220-221, 2022. e-Pub 2022. PMID: 35246349.
      23. Chaftari AM, Hachem R, Malek AE, Mulanovich VE, Szvalb AD, Jiang Y, Yuan Y, Ali S, Deeba R, Chaftari P, Raad I. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infect Dis 9(6):ofac079, 2022. e-Pub 2022. PMID: 35663286.
      24. Robinson JD, Karam-Hage M, Kypriotakis G, Beneventi D, Blalock JA, Cui Y, Gonzalez R, Tayar J, Chaftari P, Cinciripini PM. Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. Am J Addict 31(3):236-241, 2022. e-Pub 2022. PMID: 35347796.
      25. Chaftari P, Lipe DN, Wattana MK, Qdaisat A, Krishnamani PP, Thomas J, Elsayem AF, Sandoval M. Outcomes of Patients Placed in an Emergency Department Observation Unit of a Comprehensive Cancer Center. JCO Oncol Pract 18(4):OP2100478, 2022. e-Pub 2022. PMID: 34905410.
      26. Lipe DN, Bourenane SS, Wattana MK, Gaeta S, Chaftari P, Cruz Carreras MT, Manzano JG, Reyes-Gibby C. A modified emergency severity index level is associated with outcomes in cancer patients with COVID-19. Am J Emerg Med 54:111-116, 2022. e-Pub 2022. PMID: 35152119.
      27. Lipe DN, Palaskas NL, Chaftari P. Cardiotoxicity of Immune Checkpoint Inhibitors: Beyond Myocarditis. J Med Toxicol 18(1):63-64, 2022. e-Pub 2022. PMID: 34227031.
      28. Chaftari P, Chaftari AM, Hachem R, Yeung SJ, Dagher H, Jiang Y, Malek AE, Dailey Garnes N, Mulanovich VE, Raad I. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score. Cancer Med 10(23):8475-8482, 2021. e-Pub 2021. PMID: 34725958.
      29. Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clinical Infectious Diseases Journal 73(9):e2697-e2704, 2021. e-Pub 2021. PMID: 32564081.
      30. Chaftari P, Qdaisat A, Chaftari AM, Maamari J, Li Z, Lupu F, Raad I, Hachem R, Calin G, Yeung SJ. Prognostic Value of Procalcitonin, C-Reactive Protein, and Lactate Levels in Emergency Evaluation of Cancer Patients with Suspected Infection. Cancers (Basel) 13(16), 2021. e-Pub 2021. PMID: 34439240.
      31. Yeung SJ, Qdaisat A, Chaftari P, Lipe D, Merlin J, Rajha E, Wechsler A, Sandoval M, Viets J, Al-Breiki A, Shah M, Pandey R, Kamal M, Khattab O, Toale K, Wattana M, Elsayem A, Gaeta S, Brock P, Reyes-Gibby C, Alagappan K. Diagnosis and Management of Immune-Related Adverse Effects of Immune Checkpoint Therapy in the Emergency Department. J Am Coll Emerg Physicians Open 1(3):1637-1659, 2020. e-Pub 2020. PMID: 33392573.
      32. Qdaisat A, Wu W, Lin JZ, Al Soud R, Yang Z, Hu Z, Gao S, Wu CC, Liu X, Silvestre J, Hita AG, Viets-Upchurch J, Al Adwan S, Al Haj Qasem N, Cruz Carreras MT, Jacobson KL, Chaftari PS, Abdel-Razeq H, Reyes-Gibby CC, Jim Yeung SC. Clinical and Cancer-Related Predictors for Venous Thromboembolism in Cancer Patients Presenting to the Emergency Department. J Emerg Med 58(6):932-941, 2020. e-Pub 2020. PMID: 32376060.
      33. El Majzoub I, Qdaisat A, Chaftari PS, Yeung SJ, Sawaya RD, Jizzini M, Carreras MTC, Abunafeesa H, Elsayem AF. Association of emergency department admission and early inpatient palliative care consultation with hospital mortality in a comprehensive cancer center. Support Care Cancer 27(7):2649-2655, 2019. e-Pub 2019. PMID: 30474736.
      34. Maamari J, Yeung SJ, Chaftari PS. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med 37(2):376.e1-376.e2, 2019. e-Pub 2019. PMID: 30361152.
      35. El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Ann Emerg Med 73(1):79-87, 2019. e-Pub 2019. PMID: 29880440.
      36. Qdaisat A, MD, Wu W, MD, PhD, , Lin J, MD, , Soud RA, MD, , Yang Z, MD, Hu Z, MD, Gao S, MD, Wu CC, MD, Liu X, MD, Silvestre J, MD, Hita G, MD, Viets-Upchurch J, MD, Adwan SA, MD, Haj Qasem NA, MD, Cruz Carreras MT, MD, Jacobson K, MD, Chaftari P, MD, Bushnaq B, MD, Bushnaq S, MD, Meng QH, PhD, Abdel-Razeq H, MD, Reyes-Gibby C, PhD, Yeung SJ, MD, PhD. A two-part algorithm to predict cancer-associated venous thromboembolism in patients presenting to the emergency department. Support Care Cancer 27:2649–2655, 2018. e-Pub 2018.
      37. El Haddad H, Chaftari AM, Hachem R, Chaftari P, Raad II. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical infectious diseases 67(6):971-977, 2018. e-Pub 2018. PMID: 29668936.
      38. Qdaisat, Aiham, Wu, Weixin, Lin, Junzhong, Soud A, Rawan, Yang, Zhi, Hu, Zhihuang, Gao, Shujun, Wu, Carol, Silvestre, Julio, Hita, Guido, Viets-Upchurch, Jayne, Adwan A, Saif, Qasem AH, Nafi’, Jacobson, Kalen, Chaftari, Patrick, Abdel-Razeq, Hikmat, Reyes-Gibby, Cielito, Sai-Ching. Clinical decision rule for cancer-associated venous thromboembolism in patients presenting to the emergency department. Thrombosis and Haemostasis, 2018. e-Pub 2018.
      39. Reyes-Gibby CC, Wang J, Yeung SJ, Chaftari P, Yu RK, Hanna EY, Shete S. Genome-wide association study identifies genes associated with neuropathy in patients with head and neck cancer. Sci Rep 8(1):8789, 2018. e-Pub 2018. PMID: 29884837.
      40. Chaftari AM, Hachem R, Raad S, Jiang Y, Natividad E, Chaftari P, Raad I. Unnecessary Removal of Central Venous Catheters in Cancer Patients with Bloodstream Infections. Infect Control Hosp Epidemiol 39(2):1-4, 2018. e-Pub 2018. PMID: 29331162.
      41. Cruz-Carreras MT, Chaftari P, Viets-Upchurch J. Advance Care Planning: Challenges at the Emergency Department of a Cancer Care Center. Support Care Cancer 26(2):585-588, 2018. e-Pub 2018. PMID: 28918550.
      42. Karam-Hage M, Kypriotakis G, Robinson JD, Green CE, Mann G, Rabius V, Wippold R, Blalock JA, Mouhayar E, Tayar J, Chaftari P, Cinciripini PM. Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis. J Clin Psychopharmacol 38(1):34-41, 2018. e-Pub 2018. PMID: 29232312.
      43. Kypriotakis AG, PhD, Karam-Hage M, MD, Robinson JD, PhD, Zheng D, MS, Mann G, MD, Rabius V, PhD, Wippold R, RN, Lam CY, PhD, Blalock JA, PhD, Mouhayar E, MD, Tayar J, MD, Chaftari P, MD, Gonzalez R, MD, Cinciripini PM, PhD. Increasing varenicline to 3mg per day improves smoking abstinence: a propensity score analysis. Clinical psychopharmacology 38(1):34-41, 2018. e-Pub 2018.
      44. Haddad HE, Chaftari AM, Hachem R, Michael M, Jiang Y, Yousif A, Raad S, Jordan M, Chaftari P, Raad I. Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia. Sci Rep 8(1):1099, 2018. e-Pub 2018. PMID: 29348438.
      45. Cruz-Carreras MT, Chaftari P, Shamsnia A, Guha-Thakurta N, Gonzalez C. Methotrexate-induced leukoencephalopathy presenting as stroke in the emergency department. Clin Case Rep 5(10):1644-1648, 2017. e-Pub 2017. PMID: 29026563.
      46. Chaftari P, Chaftari AM, Adachi J, Hachem R, Raad S, Natividad E, Oliver N, Ellickalputhenpura B, Jiang Y, Tarrand J, Raad I. Improvement in the diagnosis of catheter-related bloodstream infections in a tertiary cancer center. Am J Infect Control 45(3):e34-e39, 2017. e-Pub 2017. PMID: 28254252.
      47. Gonzalez CE, Cruz-Carreras MT, Guha-Thakurta N, Brydges N, Chaftari P. A Rare Case of Extramedullary Plasmacytoma of the Pleura Causing Spinal Cord Compression in a Patient with Multiple Myeloma. Med Sci Case Rep 2017(4):19-23, 2017. e-Pub 2017.
      48. Cruz-Carreras MT, Chaftari P, Gonzalez C, Enojo R, Viets-Upchurch J. Emergency-department-intervention-program-for-enhancing-choice-at-the-endof-life-a-quality-improvement-project-at-a-comprehensive cancer center. Journal of Palliative Care & Medicine 7(2):10000298, 2017. e-Pub 2017.
      49. Elsayem AF, Merriman KW, Gonzalez CE, Yeung SC, Chaftari PS, Reyes-Gibby C, Todd KH. Presenting Symptoms in the Emergency Department as Predictors of Intensive Care Unit Admissions and Hospital Mortality in a Comprehensive Cancer Center. J Oncol Pract 12(5):e554-63, 2016. e-Pub 2016. PMID: 27072570.
      50. Wu W, Liu X, Chaftari P, Cruz Carreras MT, Gonzalez C, Viets-Upchurch J, Merriman K, Tu SM, Dalal S, Yeung SC. Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review. PLoS One 10(3):e0122047, 2015. e-Pub 2015. PMID: 25822612.
      51. Bazerbashi H, Merriman KW, Toale KM, Chaftari P, Cruz Carreras MT, Henderson JD, Yeung SC, Rice TW. Low tissue oxygen saturation at emergency center triage is predictive of intensive care unit admission. J Crit Care 29(5):775-9, 2014. e-Pub 2014. PMID: 24973103.

      Review Articles

      1. Cruz Carreras, MT, González Landrón, F, López, N, Padrón Alcántara, L, Markides, DM, Burk, KJ, Chaftari, P. Hematologic immune-related adverse effects of immune checkpoint inhibitors. Supportive Care in Cancer 33(10), 2025. e-Pub 2025. PMID: 41055801.
      2. Singer, ED, Elsayem, A, Nassif, T, Rodriguez, C, Zoghbi, M, Dagher, J, Yammine, N, Kamal Jomaa, M, Cruz Carreras, MT, Vu, T, Qdaisat, AZ, Yeung, SJ, Chaftari, P. Initial management and disposition of metastatic spinal cord compression in the emergency department. Annals of Medicine 57(1), 2025. e-Pub 2025. PMID: 41033840.
      3. Lipe DN, Qdaisat A, Krishnamani PP, Nguyen TD, Chaftari P, El Messiri N, Srinivasan A, Galvis-Carvajal E, Reyes-Gibby CC, Wattana MK. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics (Basel) 14(16), 2024. e-Pub 2024. PMID: 39202282.
      4. Zoghbi M, Moussa MJ, Dagher J, Haroun E, Qdaisat A, Singer ED, Karam YE, Yeung SJ, Chaftari P. Brain Metastasis in the Emergency Department: Epidemiology, Presentation, Investigations, and Management. Cancers (Basel) 16(14), 2024. e-Pub 2024. PMID: 39061222.
      5. Krishnamani PP, Sandoval M, Chaftari P, Lipe DN, Qdaisat A, Elsayem A, Wattana MK. The Value Proposition of Observation Medicine in Managing Acute Oncologic Pain. Curr Oncol Rep 24(5):595-602, 2022. e-Pub 2022. PMID: 35192121.
      6. Araji G, Maamari J, Ahmad FA, Zareef R, Chaftari P, Yeung SJ. The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review. J Immunother Precis Oncol 5(1):13-25, 2022. e-Pub 2022. PMID: 35663831.
      7. Lipe DN, Rajha E, Wechsler AH, Gaeta S, Palaskas NL, Alhajji Z, Viets-Upchurch J, Chaftari P. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. Am J Emerg Med 50:51-58, 2021. e-Pub 2021. PMID: 34274878.
      8. Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 8(1):1-6, 2020. e-Pub 2020. PMID: 32104583.
      9. Huang YW, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R. Current drug therapy for multiple myeloma. Drugs 57(4):485-506, 1999. e-Pub 1999. PMID: 10235689.

      Abstracts

      1. Chaftari PS, Krishnamani PP, Qdaisat A, Wattana MK, Lipe DN, Sandoval M, Elsayem A, Cruz Carreras MT, Yeung SJ. Utilization of oncologic emergency department observation units by cancer patients presenting with pain. The Journal of Emergency Medicine 66(1):e51, 2024. e-Pub 2024.
      2. Haddad A, Moussa M, Hachem R, Jiang Y, Dagher H, Chaftari P, Chaftari A, Raad I. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      3. Dagher H, Chaftari A, Hachem R, Jiang Y, Philip A, Mulanovich P, Haddad A, Lamie P, Dib RW, John T, Dailey Garnes NJ, Chaftari P, Raad I. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      4. Chaftari A, Dagher H, Hachem R, Jiang Y, Lamie P, Dib RW, John T, Haddad A, Philip A, Ali S, Mulanovich P, Yuan Y, Chaftari P, Raad I. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      5. Haddad A, Moussa M, Hachem R, Jiang Y, Dagher H, Chaftari P, Chaftari A, Raad I. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      6. Chaftari A, Dagher H, Hachem R, Jiang Y, Lamie P, Dib RW, John T, Haddad A, Philip A, Ali S, Mulanovich P, Yuan Y, Chaftari P, Raad I. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      7. Dagher H, Chaftari A, Hachem R, Jiang Y, Philip A, Mulanovich P, Haddad A, Lamie P, Dib RW, John T, Dailey Garnes NJ, Chaftari P, Raad I. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients. ID Week 2023 IDWeek 2023, October 11-15, 2023, at the Boston Convention and E, 2023. e-Pub 2023.
      8. Malek AE, Chaftari P, Dagher HR, Hachem R, Chaftari AM, Viola GM, Raad II. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation. ID Week 2020 Virtual Conference, Online, Oct 21, 2020 (#1636), 10/2020, 2020. e-Pub 2020.
      9. Chaftari P, MD, Chaftari A, MD, Hachem R, MD, Yeung SJ, MD, Dagher H, Jiang Y, MS, Malek A, MD, Mulanovich VE, MD, Raad I, MD. The Role of Procalcitonin (PCT) and Lactic Acid in Febrile Neutropenic Cancer Patients in an Oncological Emergency Center. ID Week 2020 Virtual Conference, Online, Oct 21, 2020 (#1228), 10/2020, 2020. e-Pub 2020.
      10. Chaftari A, Hachem R, Malek AE, Mulanovich V, Szvalb A, Jiang Y, Ali S, Deeba R, Chaftari P, Raad I. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies. ID Week 2020 Virtual Conference, Online, Oct 21, 2020 (#1257), 10/2020, 2020. e-Pub 2020.
      11. Chaftari P, MD, Chaftari A, MD, Hachem R, MD, Yeung SJ, MD, Jiang Y, MS, Malek A, MD, Mulanovich VE, MD, Raad I, MD. Potential Role of Procalcitonin in Antimicrobial Stewardship Program in Febrile Neutropenic Cancer Patients. ECCMID 2020, 2020. e-Pub 2020.
      12. Khawaja F, Chaftari P, Batista M, Jb B, Chemaly R. Outcomes of Respiratory Viral Infections in Cancer Patients on PD-1 inhibitors. ID Week 2019, 2019. e-Pub 2019.
      13. Malek A, MD, Khalil M, MD, Hachem R, MD, Chaftari AM, MD, Fares J, MD, Jiang Y, MS, Kontoyiannis DP, MD, Fossella F, MD, Chaftari P, MD, Mulanovich V, MD, Viola G, MD, Raad I, MD. Impact of Checkpoint Inhibitor Immunotherapy on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study. ID Week 2019, 2019. e-Pub 2019.
      14. Majzoub IE, Qdaisat A, Chaftari PS, Yeung SJ, Sawaya RD, Jizzini M, Cruz Carreras MT, Abunafeesa H, Elsayem AF. Association of emergency department admission and early inpatient palliative care consultation with hospital mortality in a comprehensive cancer center. Supportive Care in Cancer, 2018. e-Pub 2018.
      15. Elsayem AF, Warneke CL, Reyes-Gibby CC, Page VD, Buffardi LJ, Brock PA, Chaftari P, Alagappan K. Triple Threat of Mortality Among Advance Cancer Patients Presenting to an Emergency Department. the 2017 Palliative and Supportive Care in Oncology Symposium 31:138, 2017. e-Pub 2017.
      16. Kypriotakis G, Karam-Hage M, Robinson JD, Green CE, Zheng D, Mann G, Rabius V, Wippold R, Blalock JA, Mouhayar E, Tayar J, Chaftari P, Cincirpini PM. Improvement of Smoking Abstinence Rates with Increased Varenicline Dosage: A Propensity Score Matched Analysis. Society and Research on Nicotine & Tobacco,, 2017. e-Pub 2017.
      17. Cruz-Carreras MT, Chaftari P, Gonzalez C, Enojo R, Viets-Upchurch J. Emergency Department Intervention Program for Enhancing Choice at the Enf of Life. Mediterranean Emergency Medicine Congress, Lisbon, Portugal, 2017. e-Pub 2017.
      18. Cruz-Carreras MT, Chaftari P, Gonzalez C, Enojo R, Viets-Upchurch J. Emergency Department Intervention Program for Enhancing Choice at the End of Life: A Quality Improvement Project at a Comprehensive Cancer Center. 36th Annual Emergencies in Medicine conference and 3rd annual GREAT meeting on February 25 – March 1, 2018, 2017. e-Pub 2017.
      19. Chaftari AM, Chaftari P, Adachi J, Hachem R, Raad S, Natividad E, Oliver N, Elickalputhenpura B, Tarrand J Raad I. Improvement in the Diagnosis of Patients With Central Line Related Bloodstream Infections by Proper Blood Culture Drawing and Labeling in an Emergency Center. ID Week (Infectious Diseases Society of America), 2016. e-Pub 2016.
      20. Elsayem AF, Merriman KW, Gonzalez CE, Yeung SJ, Chaftari PS, Reyes-Gibby C, Todd KH. Presenting Symptoms in the Emergency Department as Predictors of Intensive Care Unit Admissions and Hospital Mortality in a Comprehensive Cancer Center. J of Clinical Oncology, 2016. e-Pub 2016. PMID: 27072570.
      21. Cao H, Johnson TN, Feng C, Chaftari PS. Decreasing the rate of inappropriate proton pump inhibitor use in the Emergency Center. Alcalde Leadership Conference, Frisco, Texas, April 21, 2016, 2016. e-Pub 2016.
      22. Kypriotakis AG, PhD, Karam-Hage M, MD, Robinson JD, PhD, Zheng D, MS, Mann G, MD, Rabius V, PhD, Wippold R, RN, Lam CY, PhD, Blalock JA, PhD, Mouhayar E, MD, Tayar J, MD, Chaftari P, MD, Gonzalez R, MD, Cinciripini PM, PhD. Increasing varenicline to 3mg per day improves smoking abstinence: a propensity score analysis. Society for Research on Nicotine & Tobacco, 2016. e-Pub 2016.
      23. Elsayem AF, Silvestre J, Merriman KW, Chaftari PS, Gonzalez CE, Yeung SJ. Outcome of cancer patients admitted through the emergency department (ED) of a comprehensive cancer center: A call for ED-based palliative care. J of Clinical Oncology 32:194, 2014. e-Pub 2014. PMID: 28142660.
      24. Elsayem AF, Merriman KW, Gonzalez CE, Yeung SJ, Chaftari PS, Henderson JD, Todd KH. Intensive care unit admissions and in-hospital mortality in patients admitted through the emergency department of a comprehensive cancer center. J Clin Oncol 32:5s:15, 2014. e-Pub 2014.
      25. Bazerbashi H, Merriman K, Toale K, Chaftari P, Henderson J, Cruz Carreras MT, Rice T. Does Measurement of Soft Tissue Oxygen Saturation at Triage Have a Unique Value?. DoIM Research Retreat, 2013. e-Pub 2013.
      26. Bazerbashi H, Merriman K, Hanzelka KM, Chaftari P, Cruz Carreras MT, Henderson JD, Yeung S, Rice TW. What Is the Prognostic Value of ST02 at Triage?. Chest 144(4), 2013. e-Pub 2013.
      27. Chaftari P. Emergency Center Observation Unit. CS&E Conference: Building the Bridge at the Quality Chasm, Austin, TX, 2009. e-Pub 2009.
      28. El-Sayegh S, Chaftari P, et al. Massive weight loss from gastric bypass surgery as a treatment for obstructive sleep apnea: A case control study. The Academy of Richmond, New York, 2001. e-Pub 2001.
      29. El-Sayegh S, Chaftari P, et al. The outcome of patients with obstructive sleep apnea after gastric bypass surgery. American College of Chest Physician Meeting, Las Vegas, 2000. e-Pub 2000.
      30. Chaftari P, Hajjar A, et al. The usefulness of the Epworth Sleepiness Scores alone as a predictor of sleep study outcomes. American College of Chest Physician Meeting, Chicago, 1999. e-Pub 1999.
      31. Hajjar A, Chaftari P, et al. Characteristics of patients with negative sleep studies. American College of Chest Physician Meeting, Chicago, 1999. e-Pub 1999.

      Book Chapters

      1. Chaftari P, Mouhayar E, Iliascu C, Peter Kim SAHA. Cardiac Emergencies in Cancer Patients. In: Oncologic Emergencies. Springer, 55-92, 2016.
      2. Chaftari P, Cruz-Carreras MT, Viets-Upchurch. Noninvasive Ventilation in the Prehospital Setting: Key Applications. In: Noninvasive Mechanical Ventilation: Theory, Equipment, and Clinical Applications. 2nd edition. Springer, 259-265, 2016.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top